Article Text

Download PDFPDF
Brentuximab vedotin in combination with sequential procarbazine, cyclophosphamide and prednisolone for the management of Hodgkin’s lymphoma-associated vanishing bile duct syndrome (VBDS) with severe obstructive liver failure
  1. Min Fong1,
  2. Stephen Boyle1 and
  3. Naadir Gutta2
  1. 1 Queensland Health, Brisbane, Queensland, Australia
  2. 2 Haematology, Greenslopes Private Hospital, Greenslopes, Queensland, Australia
  1. Correspondence to Dr Min Fong, m.fong{at}


We present a novel treatment protocol that was successful in the management of Hodgkin’s-associated vanishing bile duct syndrome, a rare but serious complication of Hodgkin’s lymphoma. We believe that publication of this treatment protocol and the rationale for its development will be of interest to anyone faced with treating this challenging condition.

  • haematology (drugs and medicines)
  • liver disease
  • malignant and benign haematology

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


  • Not commissioned; externally peer reviewed.

  • Contributors MF and SB drafted the manuscript. SB reviewed the literature. NG created the treatment protocol and critically revised the manuscript.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests None declared.

  • Patient consent for publication Obtained.